https://www.selleckchem.com/pr....oducts/AZD2281(Olapa
Sodium butyrate (So supplementation has been suggested to attenuate the development of non-alcoholic fatty liver disease (NAFLD). Here, we determined the therapeutic potential of SoB on NAFLD progression and molecular mechanism involved. Eight-week old C57BL/6J mice were pair-fed a fat-, fructose- and cholesterol-rich diet (FFC) or control diet (C). After 8 weeks, some mice received 0.6g SoB/kg bw in their respective diets (C+SoB; FFC+So or were maintained on C or FFC for the next 5 weeks of feeding. Liver damage, markers